Adaptive Dose Adjustment of Cisplatin in Lung Cancer
Author Information
Author(s): Schellens J H M, Planting A S T, van Zandwijk N, Ma J, Maliepaard M, van der Burg M E L, de Boer-Dennert M, Brouwer E, van der Gaast A, van den Bent M J, Verweij J
Primary Institution: The Netherlands Cancer Institute
Hypothesis
Can adaptive intrapatient dose escalation of cisplatin improve treatment outcomes in patients with advanced nonsmall cell lung cancer?
Conclusion
The study found that adaptive dose adjustments of cisplatin can be feasible and may improve treatment response in patients with advanced nonsmall cell lung cancer.
Supporting Evidence
- Cisplatin treatment showed a 27% reduction in the risk of death compared to supportive care alone.
- 40% of patients achieved a partial remission with the treatment.
- Patients who received dose adjustments had better outcomes in terms of DNA adduct levels.
Takeaway
Doctors tried changing the amount of a cancer drug called cisplatin during treatment to see if it helps patients with lung cancer feel better. It worked for some people!
Methodology
Patients with advanced nonsmall cell lung cancer received cisplatin and low-dose VP16, with doses adjusted based on individual responses and pharmacokinetic measurements.
Potential Biases
Potential biases may arise from the lack of randomization and the subjective nature of some assessments.
Limitations
The study did not include a control group for comparison and relied on historical data for some outcomes.
Participant Demographics
{"male":49,"female":27,"median_age":56,"age_range":"33-72"}
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website